Recent studies have shown that the B-cell lymphoma 6 gene (BCL6) is an oncogene that contributes to lymphoma genesis. Exon 6 of BCL6 contains a common single nucleotide polymorphism (SNP) ( − 195 C>T; dbSNP ID: rs1056932) that alters a potential binding site for an exonic splicing enhancer. We used unconditional logistic regression models to examine the association between this SNP and the risk of non-Hodgkin lymphoma (NHL) in a population-based case -control study of women residing in Connecticut (461 case patients and 535 control subjects). The B-cell lymphoma 6 gene (BCL6) was discovered during an analysis of chromosome 3q27 translocations in diffuse large B-cell lymphomas and follicular lymphomas ( 1 -3 ) . BCL6 encodes the POZ/zinc fi nger transcriptional factor Bcl6, which is necessary for germinal center formation and for the T-celldependent antibody response ( 4 ) . BCL6 is expressed early in germinal center formation, but its expression is reduced in post-germinal center cells, suggesting that Bcl6 plays a critical role in lymphopoeisis, one that, if disturbed, could contribute to lymphomagenesis ( 5 ) .
The B-cell lymphoma 6 gene (BCL6) was discovered during an analysis of chromosome 3q27 translocations in diffuse large B-cell lymphomas and follicular lymphomas ( 1 -3 ) . BCL6 encodes the POZ/zinc fi nger transcriptional factor Bcl6, which is necessary for germinal center formation and for the T-celldependent antibody response ( 4 ) . BCL6 is expressed early in germinal center formation, but its expression is reduced in post-germinal center cells, suggesting that Bcl6 plays a critical role in lymphopoeisis, one that, if disturbed, could contribute to lymphomagenesis ( 5 ) .
It has been shown that Bcl6 represses expression of a number of genes that are functionally linked to B-cell activation and differentiation (i.e., CD44, CD69, STAT1, LEU13, Blimp-1), infl ammation (i.e., IP10, CXCR4), and cell cycle control (i.e., p27kip1, cyclin D2 ) ( 6 ) . Deregulated expression of BCL6 could alter the expression or function of genes in these critical pathways, resulting in the promotion of tumorigenesis. Results of a recent study in transgenic mice suggest that BCL6 can act as an oncogene in lymphomagenesis ( 7 ) .
In view of the seminal importance of BCL6 in lymphogenesis, we examined the association between a potentially functional single nucleotide polymorphism (SNP) in BCL6 exon 6 (Ex6 − 195C>T; dbSNP ID: rs1056932) that could alter BCL6 mRNA expression and the risk of non-Hodgkin lymphoma (NHL) in a large population-based casecontrol study among women residing in Connecticut.
A detailed description of the study population has been reported previously ( 8 -12 ) . A total of 601 case patients with histologically confi rmed incident NHL and 717 population-based control subjects were enrolled and completed in-person interviews. Blood samples for genotyping were available for 461 (76.7%) case patients and 535 (74.6%) control subjects. DNA was extracted from the blood samples using phenol-chloroform extraction ( 13 ) and genotyped by a real-time polymerase chain reaction assay on an ABI 7900HT sequence detection system as described on the SNP500 website ( http:// snp500cancer.nci.nih.gov/snp.cfm?both_ snp_id=BCL6-01 ) at the Core Genotyping Facility of the National Cancer Institute ( 14 ) . The study was approved by Institutional Review Boards at Yale University, the Connecticut Department of Public Health, and the National Cancer Institute. Participants provided written informed consent.
Unconditional logistic regression models were used to estimate the association between the genetic polymorphism in the BCL6 gene and the risk of NHL by NHL subtypes. In the model, we assigned the TT, CT, and CC genotypes values of 0, 1, and 2, respectively, and treated genotype as a continuous variable for trend analyses. Odds ratios (ORs) with 95% confi dence intervals (CIs) were calculated using SAS software (version 8.02; SAS Institute, Inc., Cary, NC). All statistical tests were two-sided.
A greater proportion of NHL case patients than control subjects reported having a family history of NHL and other cancers among their fi rst-degree relatives ( tbl1 Table 1 ). There were no statistically signifi cant differences in age or race between case patients and control subjects.
We found that the homozygous C allele of the BCL6 Ex6 − 195C>T SNP was associated with an increased risk of NHL ( tbl2 Table 2 ). Compared with the TT genotype, the CC genotype was associated with statistically signifi cantly increased risks of NHL overall (OR = 2.2, 95% CI = 1.5 to 3.3), B-cell lymphoma (OR = 2.0, 95% CI = 1.3 to 3.1), and T-cell lymphoma (OR = 5.2, 95% CI = 2.0 to13.3). The association between the C allele and risk was dose dependent ( P trend = .0002, .0018, and .0016, respectively).
We also found that the homozygous C allele was associated with statistically signifi cantly increased risks of three subtypes of B-cell lymphoma: B-cell chronic lymphocytic leukemia/prolymphocytic * NHL = non-Hodgkin lymphoma; CLL/SLL = B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma; NOS = not otherwise specifi ed.
† Chi-square test (two-sided). ‡ Family history of cancer in fi rst-degree relatives. § Includes mantle cell lymphoma (n = 12), plasmacytoma (n = 1), Burkitt's lymphoma (n = 1), and unspecifi ed B-cell lymphoma (n = 17). leukemia/small lymphocytic lymphoma (CLL/SLL; OR = 3.5, 95% CI = 1.6 to 7.8), diffuse large B-cell lymphoma (OR = 2.0, 95% CI = 1.1 to 3.5), and follicular lymphoma (OR = 2.0, 95% CI = 1.1 to 3.8). Statistically signifi cant trends were observed for associations between the variant genotypes and the risks of CLL/SLL and diffuse large B-cell lymphoma ( P trend = .0029 and .016, respectively), but not between the variant genotypes and the risk of follicular lymphoma ( P trend = .11). Further analyses that were restricted to non-Hispanic white subjects produced results similar to those reported above (data not shown).
Our results, which are the fi rst evidence of an association between a BCL6 SNP and NHL from a population-based molecular epidemiology study, support the hypothesis that a common genetic variation in the BCL6 gene could contribute to lymphomagenesis. It has been reported that this same SNP is associated with an increased risk of breast cancer ( 15 ) . It is interesting to note that, in our study, the BCL6 Ex6 − 195C>T SNP was associated with multiple histologic subtypes of NHL. Although the exact mechanism(s) underlying such a phenomenon is currently unknown, this fi nding suggests that multiple lymphoma subtypes may share an early step in lymphomagenesis.
The synonymous Ex6 − 195C>T SNP, which does not change the amino acid sequence of Bcl6, is a particularly interesting genetic variant because it can potentially alter the pattern of mRNA splicing involving one of the functional domains within the BCL6 gene. We used the web-based tool ESEfi nder ( http:// exon.cshl.edu/ESE/ ) to examine the effects of this genetic variant on splicing and found that the Ex6 -195C>T SNP could potentially cause changes of these binding sites for exonic splicing enhancers that could lead to the inaccurate recognition of exon/intron boundaries or differential binding of transcription * The SNP genotype frequency in the control subjects was in Hardy-Weinberg equilibrium. Odds ratios were adjusted for age (as a continuous variable), race, and family history of NHL in fi rst-degree relatives. P values are two-sided (Wald chi-square test). NHL = non-Hodgkin lymphoma; OR = odds ratio; CI =confi dence interval; CLL/SLL= B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma; DLBL = diffuse large B-cell lymphoma; MZBL = marginal zone B-cell lymphoma; FL = follicular lymphoma. Four case patients and fi ve control subjects were excluded from the analysis because their genotypes could not be determined.
factors to the BCL6 pre-mRNA. A functional domain in the center of the BCL6 protein that could act as an autonomous transcriptional re p ression module by recruiting histone deacetylases has been characterized and mapped to a 17-amino acid sequence ( 16 ) . The SNP investigated in our study is located immediately carboxyl-terminal to this 17-amino acid sequence and could alter the binding site for exonic splicing enhancers (ESEs), which are short binding sites for serine/ arginine-rich proteins involved in multiple steps of the splicing pathway ( 17 ) . However, it is also possible that the Ex6 − 195C>T SNP is in linkage disequilibrium with another variant located in or near the BCL6 gene that is associated with an increased risk of NHL. Additional studies are needed to survey the common genetic variants across this locus, to determine the pattern of linkage disequilibrium, and to characterize the common haplotype structure. It is also possible that one or more additional SNPs, in cis , could be associated with an increased risk of NHL. Thus, additional studies should be performed in parallel with the genetic studies to investigate the functional consequences of the Ex6 − 195C>T SNP and, perhaps, of other SNPs in linkage with it.
One potential limitation of this study is that blood samples for genotype analysis were not available for all study subjects. However, we found no differences between subjects with and without blood samples in terms of age, race, family history of NHL in fi rst-degree relatives, or case -control status. Another potential concern is that a small number of case patients who had very aggressive disease may have died before the interview and thus were underrepresented in this study. Therefore, our results may not be generalizable to individuals with aggressive forms of NHL. Similarly, because our study included only women, our results may not be generalizable to men.
In summary, our study provides the fi rst evidence that genetic variation in the coding region of the BCL6 gene is associated with inherited susceptibility to NHL. Large molecular epidemiology studies should be conducted to investigate the impact of this type of SNP on the disruption of a putative splicing site in different study populations.
